Artiva Biotherapeutics Announces Exclusive Worldwide Collaboration and License Agreement with Merck to Develop Candidate CAR-NK Cell Therapies
Collaboration utilizes Artiva’s proprietary off-the-shelf allogeneic NK cell and CAR technology platforms to develop up to three CAR-NK cell therapies targeting solid tumor-associated antigens
Artiva to receive $30 million upfront payment and up to $612 million per program in potential future development and commercial milestones, and royalties on any future worldwide product sales
Artiva to develop novel CAR-NK cell therapy candidates and transfer to Merck for clinical development and commercialization
